PH1


Also found in: Medical.
AcronymDefinition
PH1Primary Hyperoxaluria Type 1
PH1Photographer's Mate First Class (Naval Rating)
PH1Pasteurella Haemolytica A1
References in periodicals archive ?
Multiple doses of lumasiran demonstrated an acceptable safety and tolerability profile in patients with PH1, with no drug related SAEs and no discontinuations from study treatment.
Offering more than 26,000 square feet of colocation space, the PH1 facility supplies a full range of premium colocation, interconnection and support services to a wide range of secure digital ecosystems.
Pepsi Cola[R] 1,13% Dif pH1 7,87% Dif pH2 Fanta[R] naranja 3,38% Dif pH1 5,62% Dif pH2 Pau pau[R] naranja 2,25% Dif pH1 3,37.5 Dif pH2 3,37.5 Dif pH2 PINGUINOS 1,13% Dif pH1 4,50 Dif pH1 3,37% Dif pH0 CHOKIS 3,38% Dif pH1 5,62 Dif pH1 Nota: Tabla derivada de grafico segmentado.
Indications included congenital hepatic fibrosis associated with polycystic kidney disease (PKD) (n=3), PH1 (n=4) and heterozygous factor H deficiency with atypical haemolytic uraemic syndrome (aHUS) (n=1).
According to the (http://www.dailymail.co.uk/sciencetech/article-2218301/Star-Wars-planet-discovered-orbiting-suns-orbited-suns.html) Daily Mail , the view from PH1 would show a double sunset with two extremely bright stars far off in the night sky.
One patient had PH1, confirmed by detection of a G1y170Arg mutation on the so-called minor allele of the AGXT gene.
PH1 had a pedigree of HA 89//P1 413(J23/HA 89*2, B[C.sub.2][F.sub.4].
Alnylam announced that it has achieved full patient enrollment in its ILLUMINATE-A Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of adults and children with primary hyperoxaluria type 1, or PH1. The study enrolled patients across 16 sites in eight countries.
We have undertaken preliminary mapping and have defined the locus to the proximal region of 5DL, which includes the location of the Ph1 homoeoallele.
The update reflects agreement on the primary endpoint for the PHYOX2 pivotal clinical trial, which is enrolling patients with PH type 1 and PH type 2, and alignment with the FDA regarding the path to full approval for the treatment of patients with PH1, as conveyed during a recent FDA Type A meeting.
The Phase 1/2 trial will be conducted initially in normal healthy volunteers, and, then, in patients with PH1. The commencement of this trial is based on encouraging pre-clinical data presented last year.
The application relates to the following premises: 15 South Methven Street, Perth, PH1 5PE The application has been made to Perth & Kinross Licensing Board.